文献速递肝病消化道肿瘤与早癌

PAGE-B评分在HIV/HBV合并感染者中预测肝细胞癌风险的外部验证

External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection.
PubMed 文献 · J Hepatol · 2023-01-21

本研究基于四个欧洲队列中2,963例接受含替诺福韦抗逆转录病毒治疗的HIV/HBV合并感染者,外部验证PAGE-B评分对肝细胞癌的预测性能。中位随访9.6年,68例发生肝细胞癌(2.58/1000人年,95%CI 2.03-3.27),合并c-index为0.77(范围0.73-0.80),PAGE-B<10对5年内肝细胞癌的阴性预测值为99.4%。结论认为PAGE-B是确定HIV/HBV合并感染者是否需要肝细胞癌筛查的有效工具。

要点

  • PAGE-B在HIV/HBV合并感染者中预测肝细胞癌的合并c-index为0.77(范围0.73-0.80),区分度良好。
  • PAGE-B<10对5年内发生肝细胞癌的阴性预测值为99.4%。
  • 将筛查限制于PAGE-B≥10者可使27%的个体免于不必要的肝细胞癌筛查。

核心结论

  • 对于HIV/HBV合并感染者,PAGE-B是确定是否需要肝细胞癌筛查的有效工具。

研究设计与样本

  • 研究纳入四个欧洲队列中HBsAg阳性、开始替诺福韦前无肝细胞癌的HIV感染者,共2,963例接受含替诺福韦抗逆转录病毒治疗者,外部验证PAGE-B评分对15年内肝细胞癌发生的预测性能。

主要发现

  • PAGE-B<10者占26.5%,10-17者占57.7%,≥18者占15.7%。
  • 中位随访9.6年期间,68例发生肝细胞癌(2.58/1000人年,95%CI 2.03-3.27)。
  • 预测15年内发生肝细胞癌的预后指数回归斜率为0.93(95%CI 0.61-1.25),合并c-index为0.77(范围0.73-0.80),均提示模型区分度良好。
  • 本研究的肝细胞癌累积发生率低于PAGE-B推导研究。
  • PAGE-B<10对5年内发生肝细胞癌的阴性预测值为99.4%;将筛查限制于PAGE-B≥10者可节省27%个体的不必要筛查。

关键数值与推荐

  • PAGE-B<10对5年内肝细胞癌发生的阴性预测值为99.4%。
  • PAGE-B预测15年内肝细胞癌的合并c-index为0.77(范围0.73-0.80)。

临床怎么用

  • 作者认为PAGE-B是确定HIV/HBV合并感染者是否需要肝细胞癌筛查的简单有效风险预测工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: HBV coinfection is common among people living with HIV (PLWH) and is the most important cause of hepatocellular carcinoma (HCC). While risk prediction tools for HCC have been validated in patients with HBV monoinfection, they have not been evaluated in PLWH. Thus, we performed an external validation of PAGE-B in people with HIV/HBV coinfection. METHODS: We included data on PLWH from four European cohorts who were positive for HBsAg and did not have HCC before starting tenofovir. We estimated the predictive performance of PAGE-B for HCC occurrence over 15 years in patients receiving tenofovir-containing antiretroviral therapy. Model discrimination was assessed after multiple imputation using Cox regression with the prognostic index as a covariate, and by calculating Harrell's c-index. Calibration was assessed by comparing our cumulative incidence with the PAGE-B derivation study using Kaplan-Meier curves. RESULTS: In total, 2,963 individuals with HIV/HBV coinfection on tenofovir-containing antiretroviral therapy were included. PAGE-B was <10 in 26.5%, 10-17 in 57.7%, and ≥18 in 15.7% of patients. Within a median follow-up of 9.6 years, HCC occurred in 68 individuals (2.58/1,000 patient-years, 95% CI 2.03-3.27). The regression slope of the prognostic index for developing HCC within 15 years was 0.93 (95% CI 0.61-1.25), and the pooled c-index was 0.77 (range 0.73-0.80), both indicating good model discrimination. The cumulative incidence of HCC was lower in our study compared to the derivation study. A PAGE-B cut-off of <10 had a negative predictive value of 99.4% for the development of HCC within 5 years. Restricting efforts to individuals with a PAGE-B of ≥10 would spare unnecessary HCC screening in 27% of individuals. CONCLUSIONS: For individuals with HIV/HBV coinfection, PAGE-B is a valid tool to determine the need for HCC screening. IMPACT AND IMPLICATIONS: Chronic HBV infection is the most important cause of hepatocellular carcinoma (HCC) among people living with HIV. Valid risk prediction may enable better targeting of HCC screening efforts to high-risk individuals. We aimed to validate PAGE-B, a risk prediction tool that is based on age, sex, and platelets, in 2,963 individuals with HIV/HBV coinfection who received tenofovir-containing antiretroviral therapy. In the present study, PAGE-B showed good discrimination, adequate calibration, and a cut-off of <10 had a negative predictive value of 99.4% for the development of HCC within 5 years. These results indicate that PAGE-B is a simple and valid risk prediction tool to determine the need for HCC screening among people living with HIV and HBV.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Surial B, Ramírez Mena A, Roumet M, et al. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. J Hepatol. 2023. PMID: 36690280. doi:10.1016/j.jhep.2022.12.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。